- Home
- RMMZ vs AVTX Comparison
RMMZ vs AVTX Comparison
Compare RMMZ & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- AVTX
- Stock Information
- Founded
- RMMZ 2022
- AVTX 2011
- Country
- RMMZ United States
- AVTX United States
- Employees
- RMMZ N/A
- AVTX N/A
- Industry
- RMMZ Investment Managers
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- AVTX Health Care
- Exchange
- RMMZ Nasdaq
- AVTX Nasdaq
- Market Cap
- RMMZ 126.3M
- AVTX 138.8M
- IPO Year
- RMMZ N/A
- AVTX 2015
- Fundamental
- Price
- RMMZ N/A
- AVTX $14.22
- Analyst Decision
- RMMZ
- AVTX Strong Buy
- Analyst Count
- RMMZ 0
- AVTX 9
- Target Price
- RMMZ N/A
- AVTX $30.14
- AVG Volume (30 Days)
- RMMZ 25.6K
- AVTX 467.6K
- Earning Date
- RMMZ 01-01-0001
- AVTX 11-06-2025
- Dividend Yield
- RMMZ 7.33%
- AVTX N/A
- EPS Growth
- RMMZ N/A
- AVTX N/A
- EPS
- RMMZ 0.82
- AVTX N/A
- Revenue
- RMMZ N/A
- AVTX $441,000.00
- Revenue This Year
- RMMZ N/A
- AVTX N/A
- Revenue Next Year
- RMMZ N/A
- AVTX N/A
- P/E Ratio
- RMMZ $19.41
- AVTX N/A
- Revenue Growth
- RMMZ N/A
- AVTX N/A
- 52 Week Low
- RMMZ $12.92
- AVTX $3.39
- 52 Week High
- RMMZ $16.99
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- RMMZ 49.82
- AVTX 67.13
- Support Level
- RMMZ $14.67
- AVTX $13.42
- Resistance Level
- RMMZ $15.13
- AVTX $14.73
- Average True Range (ATR)
- RMMZ 0.17
- AVTX 0.91
- MACD
- RMMZ -0.04
- AVTX 0.12
- Stochastic Oscillator
- RMMZ 30.63
- AVTX 78.78
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).